Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyungpook National University; Kyungpook National University Hospital
• Treatments: Leuprolide

Criteria

Inclusion Criteria:

1. Child diagnosed with CPP who has a peak-stimulated Lutenizing Hormone(LH) concentration over 5 IU/liter before initiation of therapy

2. Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls and less than 9 years in boys.

3. Tanner stage ≥2

4. Advanced bone age (Bone Age/Chronological Age >1.1)

5. Able to have the signed written informed consent provided by the patients' parents or legal guardians prior to any study-related procedures

Exclusion Criteria:

1. Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion

2. Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known chronic disease of underlying medical condition

3. Currently on or planning growth hormone treatment

4. Previous Gonadotropin-Releasing Hormone agonist treatment

5. Any patient who in opinion of the investigator should not participate in the study